NEW ORLEANS, Dec. 27, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (the "Company") (NasdaqGS: AZN), if they purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). This action is pending in the United States Distric ...

Investigation Overview - Pomerantz LLP is investigating claims on behalf of AstraZeneca investors regarding potential securities fraud or unlawful business practices [2][3] - The investigation involves AstraZeneca and certain officers and/or directors [3] Market Impact - AstraZeneca's ADR price fell $5 16 per ADR or 7 22% to close at $66 27 per ADR on November 5 2024 [5] Expanded Investigation - The fraud investigation into AstraZeneca has expanded to include several Chinese government agencies implicating dozens of senior executives at the company [6] Firm Background - Pomerantz LLP is a premier firm in corporate securities and antitrust class litigation with offices in multiple global cities [4] - The firm has a history of recovering multimillion-dollar damages awards for class members [4]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd).The MAA sought approval of Dato-DXd for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase III study.The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AstraZeneca PLC ("AstraZeneca PLC" or the "Company") (NASDAQ: AZN) investors of a class action representing investors that bought securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). AstraZeneca PLC investors have until February 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

AstraZeneca (AZN) announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.The nod i ...

U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities. AstraZeneca expects a sales hit in China, one of its most important international markets.The drugmaker's issues in China have weighed heavily on its performance of late, and its stock is down by ab ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.So What: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter category. Here's why they think AstraZeneca (AZN -0.54%), Eli Lilly (LLY 0.86%), and Vertex Pharmaceuticals (VRTX -0.08%) are unstoppable healthcare stocks to buy right now.An unstoppable stock at a great valuationDavid Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a heft ...

SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug importation, and personal information breaches. The probe has caused AstraZeneca American Depositary Shares to decline sharply and raised serious concerns about the company’s business practices in one of its largest markets. Hagens Berman has opened an investigation and urges investors in AstraZeneca American Depos ...